在精子发生过程中使用氨酸和对后代的风险
Jakob Christensen1,2, Betina B Trabjerg3,4, Julie Werenberg Dreier3,4
1Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
JAMA network open
|June 4, 2024
概括
父亲在受孕前使用氨酸与后代的出生缺陷或发育障碍无关. 这项大型研究发现,在父亲使用氨酸的儿童中,先天性形或神经发育障碍的风险没有增加.
科学领域:
- 生殖毒理学 生殖毒理学
- 发育神经生物学的发展神经生物学
- 药学流行病学 药学流行病学
背景情况:
- 在精子发生过程中,父亲对氨酸的暴露引起了对后代产性和神经发育结果的担忧.
- 目前关于父亲暴露于氨酸和后代健康的数据有限.
研究的目的:
- 研究父亲在精子生成过程中使用氨酸与后代患先天性形和神经发育障碍的风险之间的关联.
主要方法:
- 在丹麦 (1997-2017年) 进行的一项全国性队列研究包括1,235,353名儿童.
- 父亲的氨酸暴露是由父亲在怀孕前3个月内填写处方药的定义.
- 逻辑双项和考克斯回归模型被用于分别评估形和神经发育障碍的风险.
主要成果:
- 在1,235,353例分娩中,有1336例的父亲在精子生成过程中暴露于氨酸.
- 父亲对氨酸的暴露与重大先天性形风险的增加无关 (ARR,0.89;95% CI,0.67-1.18).
- 对于神经发育障碍 (AHR,1.10;95% CI,0.88-1.37) 或自闭症谱系障碍 (AHR,0.92;95% CI,0.65-1.30) 没有观察到增加的风险.
结论:
- 这项大型队列研究表明,精子生成期间父亲对氨酸的暴露与子女患先天性形或神经发育障碍的风险增加无关.
- 稳定性分析,包括剂量反应和兄弟姐妹比较,支持了这些发现.
- 这些发现有助于了解父亲使用氨酸酸的安全性.
相关概念视频
Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Spermatogenesis
102.4K
Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male...
102.4K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
122
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
122
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
Antiepileptic Drugs: Potassium Channel Activators
171
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
171
Antiepileptic Drugs: GABAergic Pathway Potentiators
385
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
385


